VERA supply chain intelligence for Vera Therapeutics, Inc.: verified suppliers, customers, debt relationships, acquisitions, and ownership data.
Data compiled by Redley Lamar · ChainSifter Intelligence
Vera Therapeutics, Inc. (VERA) is shown with relationship data already present in ChainSifter's database. Counts below come from stored supply-chain records and filing/source URLs where available; missing source URLs are not filled in or estimated.
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| ARES-TRADING-S-A | ARES-TRADING-S-A | 90% | If we breach our license agreement (Ares Agreement) with Ares Trading S.A. (Ares), an affiliate of Merck KGaA, Darmstadt, Germany, related to atacicept, or the license agreement with Novartis Interna… |
| BOARD-OF-TRUSTEES-OF-LELAND-STANFORD-JUNIOR-UNIV | BOARD-OF-TRUSTEES-OF-LELAND-STANFORD-JUNIOR-UNIV | 90% | If we breach our license agreement (Ares Agreement) with Ares Trading S.A. (Ares), an affiliate of Merck KGaA, Darmstadt, Germany, related to atacicept, or the license agreement with Novartis Interna… |
| NOVARTIS-INTERNATIONAL-PHARMACEUTICAL-AG | NOVARTIS-INTERNATIONAL-PHARMACEUTICAL-AG | 90% | If we breach our license agreement (Ares Agreement) with Ares Trading S.A. (Ares), an affiliate of Merck KGaA, Darmstadt, Germany, related to atacicept, or the license agreement with Novartis Interna… |
| OFCF-II | OFCF-II | 90% | The Company accounted for the loan syndicate on a creditor-by-creditor basis. With respect to the continuing creditors, Oxford Finance, OFCF II, and OFCF III, the Company accounted for this transacti… |
| OFCF-III | OFCF-III | 90% | The Company accounted for the loan syndicate on a creditor-by-creditor basis. With respect to the continuing creditors, Oxford Finance, OFCF II, and OFCF III, the Company accounted for this transacti… |
| OFCF-IV | OFCF-IV | 90% | With respect to the new lender, OFCF IV, the Company accounted for this transaction as an issuance of debt |
| OXFORD-FINANCE | OXFORD-FINANCE | 90% | The Company accounted for the loan syndicate on a creditor-by-creditor basis. With respect to the continuing creditors, Oxford Finance, OFCF II, and OFCF III, the Company accounted for this transacti… |
| AUPH | Aurinia Pharmaceuticals Inc. | 72% | Reciprocal relationship from AUPH graph: Reciprocal relationship from VERA graph: Reciprocal relationship from AUPH graph: Reciprocal relationship from VERA graph: Reciprocal relationship from AUPH g… |
| AUPH | Aurinia Pharmaceuticals Inc. | 72% | experienced any significant delays in obtaining any raw materials from our suppliers, we cannot provide assurance that we will not face shortages from one or more of them in the future. Please see th… |
| AZN | AstraZeneca PLC | 72% | Reciprocal relationship from AZN graph: Reciprocal relationship from VERA graph: Reciprocal relationship from AZN graph: Reciprocal relationship from VERA graph: Reciprocal relationship from AZN grap… |
| CLYM | Climb Bio, Inc. | 72% | Reciprocal relationship from CLYM graph: Reciprocal relationship from VERA graph: Reciprocal relationship from CLYM graph: ies; • the cost of nonclinical studies and clinical trials of our product ca… |
| JBIO | Jade Biosciences, Inc. | 72% | Reciprocal relationship from JBIO graph: Reciprocal relationship from VERA graph: Reciprocal relationship from JBIO graph: Reciprocal relationship from VERA graph: Reciprocal relationship from JBIO g… |
| SNYNF | Sanofi | 72% | Reciprocal relationship from SNYNF graph: Reciprocal relationship from VERA graph: experienced any significant delays in obtaining any raw materials from our suppliers, we cannot provide assurance th… |
| SNYNF | Sanofi | 72% | experienced any significant delays in obtaining any raw materials from our suppliers, we cannot provide assurance that we will not face shortages from one or more of them in the future. Please see th… |
| TVTX | Travere Therapeutics, Inc. | 72% | Reciprocal relationship from TVTX graph: Reciprocal relationship from VERA graph: Reciprocal relationship from TVTX graph: Reciprocal relationship from VERA graph: Reciprocal relationship from TVTX g… |
| TVTX | Travere Therapeutics, Inc. | 72% | experienced any significant delays in obtaining any raw materials from our suppliers, we cannot provide assurance that we will not face shortages from one or more of them in the future. Please see th… |
| Ticker | Name | Confidence | Evidence |
|---|---|---|---|
| AUPH | Aurinia Pharmaceuticals Inc. | 72% | competing technological and market developments; • maintaining our rights under our existing license agreements and any similar agreements we may enter into in the future; • negotiating favorable ter… |
| AUPH | Aurinia Pharmaceuticals Inc. | 72% | Reciprocal relationship from AUPH graph: Reciprocal relationship from VERA graph: Reciprocal relationship from AUPH graph: Reciprocal relationship from VERA graph: competing technological and market … |
| JBIO | Jade Biosciences, Inc. | 72% | Reciprocal relationship from JBIO graph: Reciprocal relationship from VERA graph: Reciprocal relationship from JBIO graph: Reciprocal relationship from VERA graph: Reciprocal relationship from JBIO g… |
| NVSEF | Novartis AG | 72% | SUMMARY OF RISKS ASSOCIATED WITH OUR BUSINESS An investment in shares of our common stock involves a high degree of risk. Below is a list of some of the material risks associated with our business. T… |
| NVSEF | Novartis AG | 72% | Reciprocal relationship from NVSEF graph: Reciprocal relationship from VERA graph: Reciprocal relationship from NVSEF graph: Reciprocal relationship from VERA graph: Reciprocal relationship from NVSE… |
| SNYNF | Sanofi | 72% | competing technological and market developments; • maintaining our rights under our existing license agreements and any similar agreements we may enter into in the future; • negotiating favorable ter… |
| SNYNF | Sanofi | 72% | Reciprocal relationship from SNYNF graph: Reciprocal relationship from VERA graph: competing technological and market developments; • maintaining our rights under our existing license agreements and … |
| TVTX | Travere Therapeutics, Inc. | 72% | competing technological and market developments; • maintaining our rights under our existing license agreements and any similar agreements we may enter into in the future; • negotiating favorable ter… |
| TVTX | Travere Therapeutics, Inc. | 72% | Reciprocal relationship from TVTX graph: Reciprocal relationship from VERA graph: Reciprocal relationship from TVTX graph: Reciprocal relationship from VERA graph: competing technological and market … |
| AMPLYX-PHARMACEUTICALS-INC | AMPLYX-PHARMACEUTICALS-INC | 62% | oduct candidates will be limited and the potential for successfully growing our business will be harmed. International trade policies, including tariffs, sanctions and trade barriers may adversely af… |
| AMRX | Amneal Pharmaceuticals, Inc. | 62% | Reciprocal relationship from AMRX graph: Reciprocal relationship from VERA graph: oduct candidates will be limited and the potential for successfully growing our business will be harmed. Internationa… |
| NOVARTIS-INTERNATIONAL-PHARMACEUTICAL-AG | NOVARTIS-INTERNATIONAL-PHARMACEUTICAL-AG | 62% | SUMMARY OF RISKS ASSOCIATED WITH OUR BUSINESS An investment in shares of our common stock involves a high degree of risk. Below is a list of some of the material risks associated with our business. T… |
| OXFORD-FINANCE-LLC | OXFORD-FINANCE-LLC | 62% | 2024 2023 AMOUNT % Other income and expenses, net $ 15,023 $ 6,023 $ 9,000 149 % 95 Other income and expenses, net, increased by $9.0 million, or 149%, to $15.0 million in the year ended December 31,… |
| Instrument | Description | Confidence | Evidence |
|---|---|---|---|
| VERA-DEBT-13326 | Xbrl Convertible | 90% | xbrl convertible detail from xbrl 2021-12-31. |
| VERA-DEBT | Debt stack $75.2M | 90% | Market cache reports total debt of $75.2M. |
| Holder | Name | Confidence | Evidence |
|---|---|---|---|
| VERA-OWNER-AVORO-CAPITAL-ADVISORS-LLC | Avoro Capital Advisors LLC | 90% | 13F overlay lists Avoro Capital Advisors LLC as top holder; 232 tracked holders. |
| Ticker | Name | Chain Index | Hops | Relationship Types |
|---|---|---|---|---|
| DSGN | Design Therapeutics, Inc. | 100.00 | 2 | |
| EDIT | Editas Medicine, Inc. | 100.00 | 2 | |
| CCEP | Coca-Cola Europacific Partners PLC | 100.00 | 2 | |
| AUPH | Aurinia Pharmaceuticals Inc. | 100.00 | 1 | ['customer', 'supplier'] |
| DBVTF | DBV TECHNOLOGIES | 100.00 | 2 | |
| BLRX | BioLineRx Ltd. | 100.00 | 2 | |
| ALXO | ALX Oncology Holdings Inc. | 100.00 | 2 | |
| CLYM | Climb Bio, Inc. | 100.00 | 1 | ['supplier'] |
| ANRO | Alto Neuroscience, Inc. | 100.00 | 2 | |
| CSLLY | CSL Limited | 100.00 | 2 | |
| CTNM | Contineum Therapeutics, Inc. | 100.00 | 2 | |
| AZN | AstraZeneca PLC | 100.00 | 1 | ['supplier'] |
| AMRX | Amneal Pharmaceuticals, Inc. | 100.00 | 1 | ['customer'] |
| BNBX | BNB Plus Corp. | 100.00 | 2 | |
| CYTOF | Altamira Therapeutics Ltd. | 100.00 | 2 | |
| ANL | Adlai Nortye Ltd. | 100.00 | 2 | |
| BIOA | BioAge Labs, Inc. | 100.00 | 2 | |
| CYTK | Cytokinetics, Incorporated | 100.00 | 2 | |
| CBIO | Crescent Biopharma, Inc. | 100.00 | 2 | |
| ATOS | Atossa Therapeutics, Inc. | 100.00 | 2 |